Home/Pipeline/TRIV-509

TRIV-509

Atopic Dermatitis

Phase 2Active

Key Facts

Indication

Atopic Dermatitis

Phase

Phase 2

Status

Active

Company

Triveni Bio

About Triveni Bio

Triveni Bio is a private, clinical-stage biotech leveraging human genetics and antibody engineering to pioneer novel treatments for immune-mediated diseases. The company's strategy is built on three foundational pillars: a genetics-informed target discovery approach, advanced antibody engineering capabilities, and a focus on pioneering novel biology. Its most advanced asset, TRIV-509, has entered Phase 2 trials for atopic dermatitis, aiming to address a root cause of disease distinct from current Th2-focused therapies. The company was recognized as a 'Fierce 15' Biotech Company in 2025, indicating strong industry validation of its platform and approach.

View full company profile

Therapeutic Areas

Immunology & Inflammation Dermatology

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
Encube-003	Encube Ethicals	Preclinical	Active
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active